


Resume



Professor Yingyao Chen is Professor of Health Services at Fudan University School of Public Health, (FUSPH), Director of the Key Lab of Health Technology Assessment (National Health Commission) at Fudan University, and Director of World Health Organization (WHO) Collaborating Centre for Health Technology Assessment and Management, Shanghai, China. In addition, he is the Associate Dean of the FUSPH, responsible for international collaborations.

He received his Bachelor of Medicine and Master of Public Health at Shanghai Medical University in 1991 and 1997, respectively, and his PhD in Management at Fudan University in 2006. He took part in a visiting scholar programme at the University of California, Los Angeles from 1999 to 2001.

His academic interests focus on health technology assessment, health policy, health economics, and hospital management. He was a principal investigator of projects funded by the WHO, World Bank, China Medical Board, National Health Commission (former Ministry of Health), Ministry of Science and Technology, National Natural Science Foundation of China (NSFC), and provincial health authorities. He has published 160 papers (142 in Chinese and 18 in English) as the first author and/or corresponding author. He is the Editor-in-chief of *Evidence Based Health Care Decision and Management*, *Health Services Evaluation* and *Disease Burdens of Main Birth Defects and Economic Evaluation of Their Preventive Strategies in China*. He is a co-author of 14 books. He is also one of core members to draft the Guideline for Health Technology Assessment in China.

He serves as a member of board of directors of Health Technology Assessment international (HTAi) (2016-2019), the coordinator of the working group of HTA at the Cochrane China Network, the Vice-Chairman of the Public Health Economics Committee affiliated to China Health Economics Association and the Vice-Chairman of Birth Defects Prevention Committee affiliated to China Healthy Birth Science Association.

His recent major research projects include:

1. Collaborating program of health technology assessment (China Medical Board, PI), focusing on HTA in PCI for Ischaemic Heart Disease, HTA in Comparing Dapagliflozin and Glimipiride as Add-on Therapy to the First-Line Metformin Therapy among Patients with Type 2 Diabetes Mellitus (T2DM) and HTA in Chemotherapies and Targeted EGFR-TKI as the First-line Therapy of Non-Small Cell Lung Cancer (NSCLC)
2. Evaluation on medical equipment (MRI) and needs (Ministry of Science and Technology, PI)
3. New medical technology adoption model and empirical study (NSFC, PI)

He and his Fudan team organize China HTA Forum in the fall every year, which is a HTA platform for policymakers, academia, healthcare providers, NGOs, industry, and young students. He produced the first Chinese Massive Open Online Course (MOOC) in HTA, which received the National Excellent MOOC Award, and promoted HTA knowledge among the Chinese audience.

A Vision Statement describing your reasons for seeking election

The main driving force for my nomination after the first term of board of director is to improve the representation of HTA researchers from the developing world, including China, among the leadership of HTAi, and to facilitate win-win cooperation between developing countries and HTAi community.

I would like to review my board of director experience during previous four years. **First, I was committed to apply for hosting the 2020 HTAi annual meeting in Shanghai, China** and then to work with Dr. Kun Zhao at China National Health Development Research Center (CNHDRC) to co-host the meeting in Beijing in 2020. It is a great opportunity for China and the first opportunity for Asian developing countries to host such an international meeting and share HTA experience with international experts and peers, and it also paves the way for the further development of HTAi since China and other developing countries urgently need to institutionalize HTA in their health systems. **Second, I, with my team, was committed to share HTA experience and knowledge in China with global HTAi community through many approaches.** We successfully organized panel sessions at HTAi meetings from 2016-2018 with global HTA experts from Argentina, China, Japan, Kazakhstan, Korea, Italy, New Zealand, and USA, focusing on *HTA with active patient participation in decision making: Transcending important partners (Tokyo, 2016)*, *Genomics and Health Technology Assessment: Global Challenges and Responses (Rome, 2017)* and *New Policies On Applying Health Technology Assessment To Action in China, Japan, And South Korea: Roles And Relevance (Vancouver, 2018)*. Through participating in other panel sessions/orals/vignettes/posters, I and my Fudan team strengthened capacity by shared learning and communication. **Third, I was committed to work for the society, mainly chairing the Interest Group Steering Committee (IGSC), being a member of Finance & Audit Committee and the Scientific Development and Capacity Building Committee, and auditing the INAHTA board meeting as an observer.** I didn't have much knowledge of IGs until I became the chair of the IGSC. Now I strongly feel that all IGs are active cells of the society to make HTAi outstanding in the global community through standardized governance with diverse autonomous patterns, better operation and sustainable development by IG members, executives and technical officers and HTAi secretariat. I hope that IGs strategy is one of the most important strategies for HTAi.

When I consider the election seriously, I would like to work on the following activities:

First, engaging in 2020 HTAi annual meeting in Beijing thoroughly. I should work with Dr. Zhao and her team at CNHDRC to take the responsibility of local co-hosts, and work with HTAi closely to make LOC and ISPC operating well. I will promote HTAi 2020 via all kinds of HTA, pharmaco-economics and

EBM meetings, work with China Medical Board and other non-profit agencies and industry in China to support the annual meeting, attract potential audience to attend the annual meeting, and mobilize tangible and intangible resources of Fudan University to prepare for the annual meeting. I am working with several IGs to prepare some potential workshops or sessions which link China with global context for HTAi 2020. In 2019 China Health Technology Assessment Forum (CHTAF), we will have significant events to promote 2020 HTAi annual meeting.

Second, developing more HTA activities to increase HTAi impacts and members' benefits through multiple ways. Although HTAi is one of unique and leading international organizations in this field, it could be more visible and play more roles in global health governance. It might require not only development or change in structure and mechanism within the society, but also initiatives taken in implementation by all stakeholders, such as all IGs, all members and the secretariats. I would be happy to push it forward, to conduct some pilots of HTA activities across countries to have more knowledge and impacts, which include research, consensus or guidelines, training, workshops, webinar, datasets, or meetings, and to engage members in more collaboration to improve members' benefits.

Third, bridging HTAi with HTA stakeholders in developing countries, including policymakers, researchers, industry, patients, and other stakeholders. As regards potential contributions from serving as a director of HTAi, I plan to link HTAi with developing countries or some multi-lateral organizations more closely, which will offer the greatest opportunity for growth for HTAi. I will share HTA evaluation, education and knowledge translation experience in China with HTAi community, especially developing countries.

Give me additional four years of time and I will help build a better HTAi in line with its strategic plan (2015-2020)!